Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China
Ablaze Pharmaceuticals, a biotech company that is focused on developing Targeted Radiotherapy (TRT) to benefit […]
Hansa Biopharma Completes Enrollment in Phase 2 Study of Imlifidase in Guillain-Barré Syndrome (GBS)
Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, today announced it has […]
ProJenX Announces Formation of Scientific Advisory Board for Development of ALS Treatment
ProJenX, a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment […]
NADclinic Group, BioStarks and Do Not Age Announce Exclusive Partnership to Revolutionise Personalised Longevity
NADclinic Group, BioStarks and Do Not Age have joined forces in an exclusive partnership to […]
PathAI Announces Collaboration with GSK on NASH Phase 2b Clinical Trial
PathAI, a leading provider of AI-powered pathology, today announced its partnership with GSK on HORIZON, […]
Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa
Nanoscope Therapeutics, today announced topline results from the Phase 2b multicenter, randomized, double-masked, sham-controlled RESTORE […]
Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors
Glyscend Therapeutics, a clinical-stage biotechnology company pioneering a new generation of orally administered polymer therapies, […]
Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics
Trobix Bio, a company utilizing CRISPR, phage, and synthetic biology technologies to develop advanced precision […]
Mathai Mammen to Join FogPharma as Chairman, President and Chief Executive Officer
FogPharma, a biopharmaceutical company committed to transforming the lives of patients through a new precision […]
Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases
Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more